Cancer: Colorectal., lung
Action: Improves cellular immune function, relieves myelosuppression
Colorectal
Seventy eight advanced colorectal cancer patients were randomly assigned to treatment group (38 patients) and control group (40 patients). Oxaliplatin 85 mg/m^2 IV infusion for 2 hours, dl. CF 200 mg/m^2 IV infusion for 2 hours followed by 5-FU 400 mg/m^2 iv infusion for 22 hours, d1-2, were administered. Every two weeks was a cycle. The control group was treated by FOLFOX4 regimen, while Guben Xiaoliu capsule was added in the treatment group. Patients were evaluated after 4 cycles. Clinical beneficial rate of treatment and contral group were 76.3% and 57.5% respectively (P<0.05).
Guben Xiaoliu capsule decreased blood hypercoagulability, improved cellular immune function of patients, relieved myelosuppression of chemotherapeutic agents and improved quality of life of patients. FOLFOX4 regimen combined with Guben Xiaoliu capsule had better effect in the treatment of advance colorectal cancer patients (Hu et al., 2007).
NSCLC
One hundred and ninety eight NSCLC in-patients were divided into the integrative treated group (Group A, 54 patients treated with chemotherapy (CT) plus GXC), the TCM treated group (Group B, 96 patients treated with GXC alone) and the chemotherapeutic group (Group C, 48 patients treated with CT alone). Randomized controlled observation was applied to Group A and Group C. The clinical effect, quality of life (QOL), adverse reaction and survival period in the three groups were observed. The immediate effective rate (CR+PR) in Groups A, B, and C was 16.7%, 3.1% and 8.3%, respectively; in Group A, it was better than in the other two groups (P<0 05).
The improvement of clinical symptoms and QOL in Groups A and B were superior to those in Group C (P<0 05). The median survival rate in the three groups was 12, 15 and 9 months, respectively, the 1-, 2-, and 3-year survival rate in Group A being 57.4%, 11.1% and 3.7%, respectively, in Group B, 67.7%, 9.4% and 3.1%, and in Group C, 39.6%, 4.2% and 0, respectively. Comparison between the three groups showed that the survival rates in the former two were higher than those in Group C (P<0 05).
Moreover, the incidence rate and degree of CT toxicity were milder in Group A than in Group C (P<0 05). GXC has definite effect in treating NSCLC; it could raise the QOL and prolong the survival period of patients, and also reduce the toxicity and enhance the efficacy of CT (Wang et al., 2004).
Lewis lung carcinoma
In vivo animal experiment was used to investigate the growth of mice tumors. Immunological (SP) and quantitative pathologic image analysis were used to investigate the microvessel density (MVD) and expression of vascular endothelial growth factor (VEGF) in tumor tissue. The inhibitory rates on mouse tumor of GC group, chemotherapy group and GC chemotherapy group were 40.58%, 52.69%, 61.09% respectively.
The inhibitory rates are significantly higher than for the control, while MVD and expression of VEGF of GC group and GC chemotherapy group and MVD of chemotherapy group decreased significantly. GC could inhibit the growth and angiogenesis of Lewis lung carcinoma of mice (Yang et al., 2004).
Formula
Sclerotium Cordyceps Chinensis (dong chong xia cao), Fructificatio Ganodermatus (ling zhi), Radix Panacis Quinque Folii (xi yang shen), Herba Epimedii (yin yang huo), Bulbus Fritillariae Thunbergii (zhe bei mu), Semen Coicis Lachryma-Jobi (yi yi ren), Hirudo seu Whitmaniae (shui zhi), Buthus Martensi (quan xie), Herba Solanum Nigrum (long kui), Rhizoma Curcumae Ezhu (e zhu), Rhizoma Smilacis Glabrae (tu fu ling), Scolopendra Subspinipes (wu gong)
References